Influence of Corn Farming on the Immune System
NCT00342121 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2020-09-10
Summary
This study will look for links between corn farming practices and short-term changes in immune function in farmers throughout the growing season. It will examine biologic effects associated with specific pesticide exposures and general planting activities, such as tillage. Farmers have an increased risk of non-Hodgkin s lymphoma and certain other blood cancers such as multiple myeloma and leukemia, but the reasons for this increase have not been identified. Findings of this study may contribute to learning the causes of cancers such as non-Hodgkin s lymphoma.
Farmers enrolled in the Agricultural Health Study (a study of pesticide applicators and their spouses in Iowa and North Carolina) and a group of control subjects selected from agricultural extension workers in Iowa may participate in this study.
The study involves six home visits to farmers and four visits to farmers to individuals in the control group. All participants will complete the following tests and procedures:
* Questionnaires and diaries During the first visit, all participants will have a medical history review, including questions about smoking and other health habits. Farmers will be asked about their farming practices, and controls will be asked about their occupations. Farmers will fill out daily diaries during short time periods of interest around certain pesticide applications to describe farming activities that day. At other times during the growing season before harvest, farmers will fill out weekly diaries describing farming activities; controls, meanwhile, will fill out weekly diaries describing their health and work activities. At home visits during the farmers growing season, all participants will fill out questionnaires about their health. Finally, farmers and controls will complete a more extensive questionnaire in the off-season, during the last home visit, to learn about their activities and exposures in the final part of the year (post-harvest for farmers).
* Urine samples: At the time of each home visit, controls will provide a urine sample that the interviewer will take that day. Farmers, too, will provide urine samples at the time of home visits, but they will also collect urine samples for a period of 4 days each during short time periods of interest after certain pesticide applications. The interviewer will collect these samples immediately at the end of these periods.
* Blood samples: At the time of each home visit, the interviewer will draw 50 ml (3.5 tablespoons) of blood.
* Telephone calls: Farmers will be called frequently from once every 2 weeks to every other day to schedule visits at the times of interest. Control subjects will also be called frequently to schedule their visits closely to those of the farmers.
Conditions
- NHL
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Laura Beane-Freeman · National Cancer Institute (NCI)
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-05-03
- Primary Completion
- 2004-01-31
- Completion
- 2008-02-05
Countries
- United States
Study Locations
More Related Trials
-
Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
NCT04871165 ·Status: UNKNOWN
-
In Vitro Studies of Immunological and Stem Cell Function in Peripheral Blood Mononuclear Cells in Patients
NCT00001336 ·Status: COMPLETED
-
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
NCT03035331 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00004211 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Immune Resistance Interrogation Study
NCT04243720 ·Status: RECRUITING
-
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
NCT02318394 ·Status: COMPLETED ·Phase: PHASE1
-
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
NCT04283539 ·Status: COMPLETED
-
MESA Treatment for NK/T Cell Lymphoma
NCT01933282 ·Status: UNKNOWN ·Phase: PHASE2
-
Investigating The Experiences of Patients In Immunotherapy Clinical Trials
NCT05435365 ·Status: NOT_YET_RECRUITING
-
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
NCT04830046 ·Status: COMPLETED
-
Vaccination Against COVID-19 in Cancer
NCT04715438 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
NCT00001582 ·Status: COMPLETED
-
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
NCT00823524 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
NCT01875653 ·Status: TERMINATED ·Phase: PHASE3
-
Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
NCT00323115 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors
NCT03989050 ·Status: WITHDRAWN
-
Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma
NCT00965224 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
NCT01239875 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection
NCT00243594 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant
NCT01852591 ·Status: COMPLETED ·Phase: NA
-
Vaccine-induced Immunity in Immunocompromised Patients
NCT06612515 ·Status: RECRUITING
-
CIML NK Cell in Head & Neck Cancer
NCT04290546 ·Status: COMPLETED ·Phase: PHASE1
-
Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors
NCT04268368 ·Status: UNKNOWN
-
Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
NCT00937183 ·Status: COMPLETED ·Phase: NA
-
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00010127 ·Status: TERMINATED ·Phase: PHASE1